- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-10-28
DOI
10.3389/fonc.2021.731535
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
- (2021) Huimei Yi et al. Frontiers in Oncology
- VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC)
- (2021) J. Huober et al. ANNALS OF ONCOLOGY
- Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer
- (2021) Armen Parsyan et al. BREAST
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
- (2021) Andrew N.J. Tutt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
- (2021) Ye Hu et al. Cancer Management and Research
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
- (2020) T. Karn et al. ANNALS OF ONCOLOGY
- Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer
- (2020) Connie Kang et al. DRUGS
- Role of Immunotherapy in Triple-Negative Breast Cancer
- (2020) Tanya E. Keenan et al. Journal of the National Comprehensive Cancer Network
- The Gαh/phospholipase C-δ1 interaction promotes autophagosome degradation by activating the Akt/mTORC1 pathway in metastatic triple-negative breast cancer
- (2020) Hui-Yu Lin et al. Aging-US
- TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
- (2020) Nadine M. Tung et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models
- (2020) Zhanfang Guo et al. Cancers
- PIK3CA in cancer: The past 30 years
- (2019) Rand Arafeh et al. SEMINARS IN CANCER BIOLOGY
- Antibody-Drug Conjugate-Based Therapeutics: State of the Science
- (2019) Michael J Birrer et al. JNCI-Journal of the National Cancer Institute
- Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
- (2019) Yi-Zhou Jiang et al. CANCER CELL
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
- (2019) S Loibl et al. ANNALS OF ONCOLOGY
- Mitotic functions of poly(ADP-ribose) polymerases
- (2019) Dea Slade BIOCHEMICAL PHARMACOLOGY
- Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance
- (2019) Meran Keshawa Ediriweera et al. SEMINARS IN CANCER BIOLOGY
- Epidrugs: targeting epigenetic marks in cancer treatment
- (2019) Cristiana Libardi Miranda Furtado et al. Epigenetics
- Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
- (2019) Sanjeevani Arora et al. ADVANCES IN THERAPY
- High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
- (2019) Simon J. Anderhub et al. MOLECULAR CANCER THERAPEUTICS
- Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
- (2019) Daniele Cretella et al. Scientific Reports
- Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
- (2018) Chia-Wei Li et al. CANCER CELL
- Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies
- (2018) Alice Lee et al. CANCER TREATMENT REVIEWS
- Update on PARP Inhibitors in Breast Cancer
- (2018) Alexandra S. Zimmer et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- Cancer epigenetics: Moving forward
- (2018) Angela Nebbioso et al. PLoS Genetics
- ATR inhibition is a promising radiosensitizing strategy for triple negative breast cancer
- (2018) Xinyi Tu et al. MOLECULAR CANCER THERAPEUTICS
- Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells
- (2018) Andrew Sulaiman et al. Cell Death & Disease
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- The clinical promise of immunotherapy in triple-negative breast cancer
- (2018) Praveen Vikas et al. Cancer Management and Research
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Triple-negative breast cancer and the potential for targeted therapy
- (2017) Jing-Ru Jhan et al. PHARMACOGENOMICS
- Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
- (2017) Jung-Min Lee et al. Oncotarget
- HDAC inhibition potentiates immunotherapy in triple negative breast cancer
- (2017) Manuela Terranova-Barberio et al. Oncotarget
- WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance
- (2017) Hongping Zheng et al. Scientific Reports
- Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer
- (2016) Ryan A. Denu et al. BMC CANCER
- The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl
- (2016) Jennifer L. Dine et al. BREAST CANCER RESEARCH AND TREATMENT
- PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
- (2016) Angel Guerrero-Zotano et al. CANCER AND METASTASIS REVIEWS
- The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
- (2016) Jennifer L. Hsu et al. CANCER AND METASTASIS REVIEWS
- Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer
- (2016) Nidal E. Muvarak et al. CANCER CELL
- New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer
- (2016) Sherry X. Yang et al. CANCER TREATMENT REVIEWS
- Differential expression of the epigenetic methylation-related protein DNMT1 by breast cancer molecular subtype and stromal histology
- (2016) Eunah Shin et al. Journal of Translational Medicine
- Targeting the cancer epigenome for therapy
- (2016) Peter A. Jones et al. NATURE REVIEWS GENETICS
- Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
- (2016) Hope S. Rugo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lateral Thinking: How Histone Modifications Regulate Gene Expression
- (2016) Moyra Lawrence et al. TRENDS IN GENETICS
- Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
- (2015) Melinda L. Telli et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
- (2015) William M. Sikov et al. JOURNAL OF CLINICAL ONCOLOGY
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Targeting Mitosis in Cancer: Emerging Strategies
- (2015) Carmen Dominguez-Brauer et al. MOLECULAR CELL
- Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor
- (2015) Y. Zhao et al. ONCOLOGIST
- Diagnostic and prognostic epigenetic biomarkers in cancer
- (2015) Pedro Costa-Pinheiro et al. Epigenomics
- Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer
- (2014) Xichun Hu et al. INTERNATIONAL JOURNAL OF CANCER
- Multicentre phase II trial of bevacizumab combined with docetaxel–carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
- (2013) H. R. Kim et al. ANNALS OF ONCOLOGY
- Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
- (2013) B. Gerber et al. ANNALS OF ONCOLOGY
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
- (2013) David Cameron et al. LANCET ONCOLOGY
- Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
- (2012) F. Andre et al. ANNALS OF ONCOLOGY
- Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial
- (2012) Adam Brufsky et al. BREAST CANCER RESEARCH AND TREATMENT
- Cancer Epigenetics: From Mechanism to Therapy
- (2012) Mark A. Dawson et al. CELL
- DNA Methylation and Its Basic Function
- (2012) Lisa D Moore et al. NEUROPSYCHOPHARMACOLOGY
- First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study
- (2012) Christoph Thomssen et al. ONCOLOGY
- Targeting EGFR in Triple Negative Breast Cancer
- (2012) Naoto T. Ueno et al. Journal of Cancer
- Functional Activation of the Estrogen Receptor- and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole
- (2011) G. J. Sabnis et al. CANCER RESEARCH
- High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells
- (2011) J. Daniel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Use of molecular markers for predicting therapy response in cancer patients
- (2010) Michael J. Duffy et al. CANCER TREATMENT REVIEWS
- Novel Treatment Approaches for Triple-Negative Breast Cancer
- (2010) Melinda L. Telli et al. Clinical Breast Cancer
- Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
- (2009) B. K. Linderholm et al. ANNALS OF ONCOLOGY
- Triple-negative breast cancer--current status and future directions
- (2009) O. Gluz et al. ANNALS OF ONCOLOGY
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer
- (2009) D. Zhang et al. CLINICAL CANCER RESEARCH
- Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity
- (2008) Giuseppe Viale et al. BREAST CANCER RESEARCH AND TREATMENT
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search